Please, you guys are missing the other obvious possibility.
TN stays as is, promotes Austedo, Copaxone, frem to neuros
TP and TR merge. TP does austedo to psychs
TR does whatever respy med they decide to keep promoting and picks up Frem primary care
TR could potentially also get psych targets that TP can't reach.
Damn check out the latest posts on the Teva Neuroscience board. There is a Civil War going on between the Psychiatry team and the Neuro team. Apparently no one knows what the hell is going on with Austedo.
This really needs to get fixed quick before another failed Teva launch or this company will be done before you know it. With huge stakes on the line for the migraine product, this certainly doesnt look good.
Damn check out the latest posts on the Teva Neuroscience board. There is a Civil War going on between the Psychiatry team and the Neuro team.
Please. The migraine drug WILL fail but not because of that. First Amgen has a migraine drug out before Teva. Compare the two and it's a hands down victory for Amgen on the drug data alone.
Now compare the Amgen leadership and sales force compared to Teva's and its goodnight Irene.
That statement is exactly why TR is an entry level role, you are too stupid to understand or worse too lazy to read the clinical trials for all the products and understand what it means with pathways, efficacy, and real world application for patients.
Amgen has the weakest product of all companies, a very soft sales force that is barely a notch about TR, but they do have the greatest resources. Lilly has the best Marketing Machine, Sales is a mess after downsizes for what feels like every year for a decade, but their product is strong because it is the same path to CGRP as Teva's (which is why Lilly is being sued, they stole it and are desperate so they are willing to take their chances in a U.S courtroom against a Foreign Organization. Then is last to the party, Alder, but maybe the most intriguing because Physicians will be making money off of the use of that product/procedure.
Long story short, Teva has a product that can compete, but no financial resources and an unknown structure for sales. Regardless of what is rolled out next week, Teva will end up with the lowest headcount in this space and no chance to win in Neuro with TN. Internally they know this so you will see solo territories to allow performance based terminations in the many placed that TN will have Zecuity like numbers and not just at the rep level, the same percentage of failures exist in Manager and Director roles. Copaxone promotion is done soon regardless of revenue so the division can't hide behind that security blanket as the excuse to justify failure as they did with Azilect, Zecuity, and now Austedo. Which means the hilariously awful days filled with a total of 4 calls, backwards product trends, and both reps always together is DONE
Not sure if Teva can turn this disaster around, but at least common sense is finally present and decisions are being made from above to at least give the comeback a chance
That statement is exactly why TR is an entry level role, you are too stupid to understand or worse too lazy to read the clinical trials for all the products and understand what it means with pathways, efficacy, and real world application for patients.
Amgen has the weakest product of all companies, a very soft sales force that is barely a notch about TR, but they do have the greatest resources. Lilly has the best Marketing Machine, Sales is a mess after downsizes for what feels like every year for a decade, but their product is strong because it is the same path to CGRP as Teva's (which is why Lilly is being sued, they stole it and are desperate so they are willing to take their chances in a U.S courtroom against a Foreign Organization. Then is last to the party, Alder, but maybe the most intriguing because Physicians will be making money off of the use of that product/procedure.
Long story short, Teva has a product that can compete, but no financial resources and an unknown structure for sales. Regardless of what is rolled out next week, Teva will end up with the lowest headcount in this space and no chance to win in Neuro with TN. Internally they know this so you will see solo territories to allow performance based terminations in the many placed that TN will have Zecuity like numbers and not just at the rep level, the same percentage of failures exist in Manager and Director roles. Copaxone promotion is done soon regardless of revenue so the division can't hide behind that security blanket as the excuse to justify failure as they did with Azilect, Zecuity, and now Austedo. Which means the hilariously awful days filled with a total of 4 calls, backwards product trends, and both reps always together is DONE
Not sure if Teva can turn this disaster around, but at least common sense is finally present and decisions are being made from above to at least give the comeback a chance
Here's the issue--Teva will not have the HO support that is needed for Frem, regardless of who is promoting. I know we like to think HO does nothing, but when you have a question, isn't it nice to get an answer in the same day/week? With Home Office's moving, I don't think this will be a reality. Teva will throw $ at Frem, it is the TOP company priority, but it might not matter if you have everyone leaving.
Here's the issue--Teva will not have the HO support that is needed for Frem, regardless of who is promoting. I know we like to think HO does nothing, but when you have a question, isn't it nice to get an answer in the same day/week? With Home Office's moving, I don't think this will be a reality. Teva will throw $ at Frem, it is the TOP company priority, but it might not matter if you have everyone leaving.
You field people are so clueless. I hope they shit can the lot of you.
LOL,
The only useless people so far that have been shit canned are from the HO, like Krissy Corny.
Boy his job was sooooooo integral to our success. So much so that ever since his last day, TR has been running exactly as it had been while he was here getting paid for adding no value.
Same will go for the rest of the HO jobs. Leave and we won't even know you're gone.
Like hell you won't.
He and Mark S were both tools. They will never make it anywhere else.
You talk about useless HO people? How about Fish Gills? Sits on his midget A** all day watching the golf channel adding nothing of value. Days are numbered.
Sorry field colleagues, but HO got us on that one. Ain't NOONE as worthless as fishy
